$791 Million is the total value of Atlas Venture Life Science Advisors, LLC's 17 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 6.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | $290,980,000 | -33.3% | 6,875,698 | 0.0% | 36.79% | -8.3% | |
| DYN | Dyne Therapeutics, Inc. | $86,132,000 | -18.9% | 8,934,902 | 0.0% | 10.89% | +11.6% | |
| DAWN | Day One Biopharmaceuticals, Inc. | $81,360,000 | -41.1% | 8,201,638 | 0.0% | 10.29% | -19.0% | |
| GBIO | Generation Bio, Co. | $60,767,000 | +3.7% | 8,278,876 | 0.0% | 7.68% | +42.7% | |
| AVTE | Aerovate Therapeutics, Inc. | $56,894,000 | +55.5% | 3,103,879 | 0.0% | 7.19% | +114.0% | |
| REPL | Replimune Group, Inc. | $54,499,000 | -37.3% | 3,209,627 | 0.0% | 6.89% | -13.8% | |
| New | Vigil Neuroscience, Inc. | $41,033,000 | – | 5,836,874 | +100.0% | 5.19% | – | |
| AKRO | Akero Therapeutics, Inc. | $31,676,000 | -32.9% | 2,232,251 | 0.0% | 4.00% | -7.6% | |
| IKNA | Ikena Oncology, Inc. | $30,611,000 | -51.4% | 5,018,178 | 0.0% | 3.87% | -33.0% | |
| Xilio Therapeutics, Inc. | $19,509,000 | -55.8% | 2,759,344 | 0.0% | 2.47% | -39.2% | ||
| MGTA | Magenta Therapeutics, Inc. | $10,082,000 | -34.5% | 3,476,536 | 0.0% | 1.28% | -9.9% | |
| SPRO | Spero Therapeutics, Inc. | $8,971,000 | -45.7% | 1,031,160 | 0.0% | 1.13% | -25.2% | |
| GMTX | Gemini Therapeutics, Inc. | $7,304,000 | -52.2% | 5,254,365 | 0.0% | 0.92% | -34.3% | |
| AVRO | AvroBio, Inc. | $5,968,000 | -65.7% | 4,520,863 | 0.0% | 0.76% | -52.8% | |
| FSTX | F-star Therapeutics, Inc. | $2,128,000 | -29.3% | 599,524 | 0.0% | 0.27% | -2.5% | |
| VRDN | Viridian Therapeutics, Inc. | $1,665,000 | -6.5% | 90,072 | 0.0% | 0.21% | +28.0% | |
| COGT | Sell | Cogent Biosciences, Inc. | $1,397,000 | -27.0% | 186,487 | -16.4% | 0.18% | +0.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kymera Therapeutics, Inc. | 8 | Q3 2023 | 40.1% |
| Day One Biopharmaceuticals, Inc. | 8 | Q3 2023 | 26.8% |
| Dyne Therapeutics, Inc. | 8 | Q3 2023 | 15.4% |
| Replimune Group, Inc. | 8 | Q3 2023 | 9.4% |
| Generation Bio, Co. | 8 | Q3 2023 | 9.1% |
| Aerovate Therapeutics, Inc. | 8 | Q3 2023 | 7.2% |
| Akero Therapeutics, Inc. | 8 | Q3 2023 | 4.3% |
| Ikena Oncology, Inc. | 8 | Q3 2023 | 5.8% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 4.1% |
| AVROBIO INC | 8 | Q3 2023 | 1.6% |
View Atlas Venture Life Science Advisors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-05-16 |
View Atlas Venture Life Science Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.